Congestive heart failure chronic pharmacotherapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 22: Line 22:
;Shown below is an image that summarizes the steps in the chronic management of patients with heart failure.
;Shown below is an image that summarizes the steps in the chronic management of patients with heart failure.
[[Image:Systolic_Heart_failure.png‎|center|600px|Management of chronic heart failure]]
[[Image:Systolic_Heart_failure.png‎|center|600px|Management of chronic heart failure]]
==References==
{{Reflist|2}}

Revision as of 19:57, 11 November 2012

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure chronic pharmacotherapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure chronic pharmacotherapy

CDC on Congestive heart failure chronic pharmacotherapy

Congestive heart failure chronic pharmacotherapy in the news

Blogs on Congestive heart failure chronic pharmacotherapy

Directions to Hospitals Treating Congestive heart failure chronic pharmacotherapy

Risk calculators and risk factors for Congestive heart failure chronic pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Assistant editor-in-chief Rim Halaby

Overview

The chronic management of heart failure aims first to treat the symptoms of the patient and improve the exercise tolerance and quality of life. The use of diuretics and regular assessment of the patient's weight helps in avoiding excess body fluids that cause the symptoms of dyspnea and orthopnea. In addition, the treatment of heart failure also aims to decrease the rate of hospitalization and associated morbidity and mortality. Hence, all patients with heart failure should take ACE inhibitors (or ARB) and beta blockers. If the patient remained symptomatic, further management is advised.

Chronic Pharmacotherapy

The goals of the treatment of heart failure are:

  • Improvement of the symptoms
  • Decreased morbidity and mortality

The management of chronic heart failure includes:

  • Improvement of the symptoms by the use of diuretics: In fact diuretics help in maintaining a normal fluid status and decrease pulmonary edema that causes dyspnea and orthopnea[1].
  • Decrease mortality and morbidity by the use of ACE inhibitors and beta blockers[2]
  • Treatment of the underlying cause of heart failure: hypertension, ischemic heart disease, valve abnormalities.
  • Treatment of other non cardiac diseases that might contribute to the symptoms of heart failure like diabetes and hyperthyroidism[3].
  • Diet: Low salt[4]
  • Weight management to check for fluid overload
  • Vaccines for influenza and pneumococcus[5].
Shown below is an image that summarizes the steps in the chronic management of patients with heart failure.
Management of chronic heart failure
Management of chronic heart failure

References

  1. Michael Felker G (2010). "Diuretic management in heart failure". Congest Heart Fail. 16 Suppl 1: S68–72. doi:10.1111/j.1751-7133.2010.00172.x. PMID 20653715.
  2. Shiokawa Y (1975). "Proceedings: Streptococcus surveys in Ryukyu Islands, Japan". Jpn Circ J. 39 (2): 168–71. PMID 1117548.
  3. DeGroot WJ, Leonard JJ (1970). "Hyperthyroidism as a high cardiac output state". Am Heart J. 79 (2): 265–75. PMID 4903771.
  4. Evangelista LS, Shinnick MA (2008). "What do we know about adherence and self-care?". J Cardiovasc Nurs. 23 (3): 250–7. doi:10.1097/01.JCN.0000317428.98844.4d. PMC 2880251. PMID 18437067.
  5. Martins Wde A, Ribeiro MD, Oliveira LB, Barros Lda S, Jorge AC, Santos CM; et al. (2011). "Influenza and pneumococcal vaccination in heart failure: a little applied recommendation". Arq Bras Cardiol. 96 (3): 240–5. PMID 21271169.